Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Net Cash Flow (2021 - 2025)

Krystal Biotech's Net Cash Flow history spans 5 years, with the latest figure at $104.3 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 466.0% year-over-year to $104.3 million; the TTM value through Dec 2025 reached $151.2 million, up 1262.27%, while the annual FY2025 figure was $151.2 million, 1262.27% up from the prior year.
  • Net Cash Flow for Q4 2025 was $104.3 million at Krystal Biotech, up from $39.1 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $135.1 million in Q2 2023 and bottomed at -$72.6 million in Q2 2021.
  • The 5-year median for Net Cash Flow is -$13.8 million (2023), against an average of $11.4 million.
  • The largest YoY upside for Net Cash Flow was 466.0% in 2025 against a maximum downside of 7486.15% in 2025.
  • A 5-year view of Net Cash Flow shows it stood at $54.6 million in 2021, then plummeted by 144.79% to -$24.5 million in 2022, then skyrocketed by 39.62% to -$14.8 million in 2023, then crashed by 92.97% to -$28.5 million in 2024, then surged by 466.0% to $104.3 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Net Cash Flow are $104.3 million (Q4 2025), $39.1 million (Q3 2025), and $44.0 million (Q2 2025).